financetom
Business
financetom
/
Business
/
PVR-INOX plans to shut down around 50 cinema screens over next 6 months
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
PVR-INOX plans to shut down around 50 cinema screens over next 6 months
May 16, 2023 12:26 PM

Leading cinema exhibitor PVR INOX plans to close around 50 loss-making screens, having an accelerated depreciation. "The company plans to shut down approximately 50 cinema screens over the next 6 months," said PVR INOX in its investor’s update for the fourth quarter and financial year ending of March 31, 2023.

Share Market Live

NSE

These properties are loss-making, or housed in malls which have reached the end of their life cycle with little hope of any revival.

"The company has taken an accelerated charge of the depreciation in its books and written off the WDV of assets," it said.

PVR-INOX Ltd has been created after the merger of two leading cinema brands PVR Ltd and INOX Leisure. The merger was effective from February 6, 2023.

Also Read: PVR-Inox focus on penetrating further in South India markets

The merged entity is operating 361 cinemas with 1,689 screens across 115 cities by the end of FY23 in India and Sri Lanka.

Karan Taurani SVP of Elara Capital said, "There will be Rs 100 million of EBITDA impact (savings) by closing down of 50 screens.

Most of these screens are across Tier I & II markets, he added.

Besides PVR INOX would continue to expand and intends to open 150-175 screens in FY24, it said.

"Of these, 9 screens have been opened till date, 15 screens are awaiting license for commercial opening and 152 screens are currently under various stages of fit out," it said.

It has realigned all upcoming handovers of new sites for fitouts till the time business fully recovers.

”The company has robust pipeline of screens signed up for development over the next 5 years,” it added.

PVR INOX had on Monday reported a consolidated net loss of Rs 333.99 crore and revenue from operations was at Rs 1,143.17 crore for the fourth quarter that ended on March 31, 2023.

"We believe increased footfall growth is the only key driver of revenue growth in FY24, as SPH (Spend per head)/ATP (Average Ticket Price) are 16%/30% higher than pre-COVID level," said Taurani.

Management is not concerned about losing some screens in the pipeline since there is a huge opportunity.

Also Read: Tech analysts see upside in these stocks

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Property developer Howard Hughes raises 2025 cash flow forecast by $30 mln
Property developer Howard Hughes raises 2025 cash flow forecast by $30 mln
Nov 10, 2025
Overview * Howard Hughes Q3 net income per share rises to $2.02 from $1.95 yr/yr * Company raises full-year 2025 adjusted operating cash flow guidance by $30 mln * Howard Hughes contracts $1.4 bln in future condo sales revenue Outlook * Howard Hughes raises full-year 2025 Adjusted Operating Cash Flow guidance to $440 mln * Company increases full-year 2025 MPC...
Editas Medicine Q3 net loss narrows, beats expectations
Editas Medicine Q3 net loss narrows, beats expectations
Nov 10, 2025
Overview * Editas Q3 net loss decreases to $25.1 mln, beating analyst expectations * Collaboration revenue rises to $7.5 mln, driven by BMS milestone achievement * Company extends cash runway into Q3 2027, supporting EDIT-401 progression Outlook * Editas plans to submit IND/CTA for EDIT-401 by mid-2026 * Company aims for initial human proof-of-concept data for EDIT-401 by end-2026 *...
CervoMed Q3 net loss widens
CervoMed Q3 net loss widens
Nov 10, 2025
Overview * CervoMed Q3 2025 net loss of $7.7 mln misses analyst expectations * Cash position decreased to $27.3 mln as of September 30, 2025 Outlook * CervoMed plans to initiate a global pivotal Phase 3 trial in DLB in H2 2026 * Company expects initial biomarker data from Phase 2a FTD trial in 2026 * CervoMed ( CRVO )...
BRIEF-Arcline Investment Management To Acquire Novaria Group From KKR For $2.2 Billion
BRIEF-Arcline Investment Management To Acquire Novaria Group From KKR For $2.2 Billion
Nov 10, 2025
Nov 10 (Reuters) - KKR & Co Inc ( KKR ): * ARCLINE INVESTMENT MANAGEMENT TO ACQUIRE NOVARIA GROUP FROM KKR FOR $2.2 BILLION * KKR - NOVARIA'S 1,600 EMPLOYEES TO RECEIVE CASH PAYOUTS UPON DEAL CLOSE Source text: Further company coverage: ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved